DYAX AND TRUBION COLLABORATE ON THERAPEUTICS AND DIAGNOSTICS DISCOVERY

Dyax entered into a nonexclusive agreement with Trubion Pharmaceuticals in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion's targets in the oncology and inflammation area.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=6550740)